REGION VI RCE - NONHUMAN PRIMATE CORE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 为了响应NIAID的号召，创建强大的基础设施和多方面的研发活动，应用最好的基础、翻译和临床科学来生成新的诊断、治疗和疫苗对策，以应对A、B和C类病原体作为生物恐怖主义代理人的威胁，德克萨斯州、新墨西哥州、俄克拉何马州、阿肯色州和路易斯安那州的22家机构将他们的精力、创造力和资源结合在一起，创建了西部(Vl区)生物防御和新发传染病卓越中心(WRCE)。九个科学核心将提供最先进的蛋白质组学、基因组学、标准化的小动物和非人类灵长类传染病模型、BSL-4实验室设施和GLP扩大生产，以及计算生物学的交叉功能和简化的疫苗和药物翻译开发流程，从而获得FDA的批准。传统上相互竞争的机构之间一贯强烈的合作精神已经建立了一个由项目、核心和管理组成的相互关联的网络，随着该中心的实施，该网络将得到加强和蓬勃发展。这个互动研究项目网络和核心资源设施的指导将在一个全面的行政计划下执行，通过履行一个共同主题的精心设计的科学战略，为国家的生物防御任务做出重大贡献；在宿主-病原体、基于生物的新型疫苗开发、诊断和针对生物制剂的治疗方面的合作。 有一个明确的共识，即非人类灵长类动物将是NIAID A类和B类代理人治疗和疫苗开发的必要组成部分。对于这些代理人中的许多人来说，人体试验将非常有限或不可能。此外，还需要适当的动物BL3设施和在BL3和BL4条件下接受过处理灵长类动物的培训的人员，以确保有效和及时地将治疗和疫苗方面的进展转移给人类。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. In response to NIAID's call for the creation of strong infrastructure and multifaceted research and development activities applying the best basic, translational, and clinical science to the generation of new diagnostic, therapeutic and vaccine countermeasures for Category A, B, and C pathogens posing threats as agents of bioterrorism, 22 institutions in Texas, New Mexico, Oklahoma, Arkansas, and Louisiana have combined their energy, creativity, and resources to create the Western (Region Vl) Center of Excellence for Biodefense and Emerging Infectious Diseases (WRCE). Nine scientific cores will provide access to state-of-the-art proteomics, genomics, standardized small animal and non-human primate models of infectious diseases, BSL-4 laboratory facilities, and GLP scale-up production, as well as crosscutting functions in computational biology and a streamlined process for translational development of vaccines and drugs leading to FDA approval. A consistently strong spirit of cooperation among traditionally competing institutions has established an interlocking network of projects, cores, and administration that will strengthen and flourish as the Center is implemented. The guidance of this network of interactive research projects and core resource facilities will be executed under a comprehensive administrative plan to contribute substantially to the nation's biodefense mission by fulfilling a carefully crafted scientific strategy on a common theme; collaborations for host-pathogen, biology-based development of novel vaccines, diagnostics, and therapeutics against biothreat agents. There is a clear consensus that nonhuman primates will be a necessary part of the development of therapeutics and vaccines for the NIAID Class A and Class B agents. For many of these agents, human trials will be very limited or impossible. In addition, appropriate animal BL3 facilities and personnel trained in the handling of primates under BL3 and BL4 conditions will be necessary in order to ensure efficient and timely transfer of advances in therapeutics and vaccines to the human population.